First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.7086
Abstract: Importance Recently, new drugs have been approved for the first-line treatment of metastatic renal cell carcinoma (mRCC). Nivolumab plus ipilimumab significantly increases overall survival for intermediate- and poor-risk patients with mRCC. However, considering the high… read more here.
Keywords: first line; sunitinib; nivolumab plus; plus ipilimumab ... See more keywords
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.5409
Abstract: Importance Increased survival with immune checkpoint inhibitors has been reported for patients with obesity vs a normal body mass index (BMI). However, the association of obesity with the safety of immune checkpoint inhibitors warrants study.… read more here.
Keywords: nivolumab plus; patients obesity; plus ipilimumab; grade iraes ... See more keywords
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34296
Abstract: First‐line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)‐negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; read more here.
Keywords: nivolumab plus; plus chemotherapy; first line; chinese patients ... See more keywords
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01926-0
Abstract: Nivolumab plus cabozantinib improved progression-free survival and overall survival compared with sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC) according to CheckMate 9ER study. A Markov model was developed to compare the… read more here.
Keywords: first line; plus cabozantinib; nivolumab plus; advanced renal ... See more keywords
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
Sign Up to like & getrecommendations! Published in 2022 at "ESMO Open"
DOI: 10.1016/j.esmoop.2022.100394
Abstract: Background Nivolumab plus ipilimumab demonstrated clinically meaningful improvement in efficacy versus chemotherapy with a manageable safety profile in patients with advanced non-small cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% or read more here.
Keywords: nivolumab plus; chemotherapy; plus ipilimumab; checkmate 227 ... See more keywords
Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "European urology"
DOI: 10.1016/j.eururo.2018.07.019
Abstract: Expert's summary: Checkmate 214 is a randomised trial comparing the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab (IN) in combination with sunitinib in previously untreated metastatic renal cell carcinoma (mRCC). The results showed significantly better… read more here.
Keywords: cell carcinoma; renal cell; nivolumab plus; plus ipilimumab ... See more keywords
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Sign Up to like & getrecommendations! Published in 2021 at "The Lancet"
DOI: 10.1016/s0140-6736(20)32714-8
Abstract: BACKGROUND Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including… read more here.
Keywords: chemotherapy; malignant pleural; plus ipilimumab; group ... See more keywords
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Sign Up to like & getrecommendations! Published in 2021 at "The Lancet"
DOI: 10.1016/s0140-6736(21)00797-2
Abstract: BACKGROUND First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line… read more here.
Keywords: chemotherapy alone; gastro oesophageal; gastric gastro; plus chemotherapy ... See more keywords
Kidney cancer: Antibody pincer movement challenges sunitinib as standard therapy
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Urology"
DOI: 10.1038/nrurol.2018.47
Abstract: phase III trial show that overall survival and objective response rate (ORR) were significantly higher in patients with advanced intermediate-risk or poor-risk renal cell carcinoma (RCC) treated with nivolumab plus ipilimumab than in those receiving… read more here.
Keywords: risk; treatment; nivolumab plus; cancer ... See more keywords
Nivolumab plus ipilimumab in malignant pleural mesothelioma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2102482
Abstract: ABSTRACT Introduction Unresectable pleural mesothelioma is a poor prognosis disease. Improvement in overall survival (OS) has been shown with PEMETREXED combined with CISPLATIN. BEVACIZUMAB combined with chemotherapy is associated with an improvement in OS, compared… read more here.
Keywords: malignant pleural; pleural mesothelioma; mesothelioma; ipilimumab malignant ... See more keywords
Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Sign Up to like & getrecommendations! Published in 2022 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyac009
Abstract: BACKGROUND Immune checkpoint inhibitors cause various immune-related adverse events. The present study examined the association between the incidence of immune-related adverse events and survival outcomes in patients treated with nivolumab plus ipilimumab for patients with… read more here.
Keywords: immune related; related adverse; nivolumab plus; adverse events ... See more keywords